In Vitro Responsiveness of Glioma Cell Lines to Multimodality Treatment With Radiotherapy, Temozolomide, and Epidermal Growth Factor Receptor Inhibition With Cetuximab
- 1 July 2007
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 68 (3) , 873-882
- https://doi.org/10.1016/j.ijrobp.2007.03.002
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiformeJournal of Neuro-Oncology, 2005
- Temozolomide Combined with Irradiation as Postoperative Treatment of Primary Glioblastoma MultiformeStrahlentherapie und Onkologie, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab Augments Radiation Effects in Glioblastoma Multiforme in Vitro and in VivoNeurosurgery, 2005
- Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximabJournal of Clinical Oncology, 2004
- Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant GliomaJournal of Clinical Oncology, 2003
- Assembly of Cell Regulatory Systems Through Protein Interaction DomainsScience, 2003
- Epidermal growth factor receptor as a therapeutic target in head and neck cancerSeminars in Radiation Oncology, 2002
- An analysis of dose-effect relationship in the radiotherapy of malignant gliomasInternational Journal of Radiation Oncology*Biology*Physics, 1979
- Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomasJournal of Neurosurgery, 1978